Baseline demographic and clinical characteristics of patients with PAH-CHD in Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1
| Characteristic | Placebo (n=12) | Riociguat 2.5 mg–maximum (n=15) | Riociguat 1.5 mg–maximum (n=8) | Total (n=35) |
|---|---|---|---|---|
| Female, n (%) | 10 (83) | 13 (87) | 6 (75) | 29 (83) |
| Age, mean±SD (years) | 40±16 | 35±14 | 41±15 | 38±15 |
| Body mass index, mean±SD (kg/m2) | 24±3 | 21±2 | 24±5 | 23±4 |
| CHD subtype, n (%) | ||||
| Corrected atrial septal defect | 6 (50) | 5 (33) | 3 (38) | 14 (40) |
| Corrected ventricular septal defect | 3 (25) | 7 (47) | 2 (25) | 12 (34) |
| Corrected persistent ductus arteriosus | 3 (25) | 2 (13) | 3 (38) | 8 (23) |
| Missing | 0 | 1 (7) | 0 | 1 (3) |
| WHO FC II/III, % | 58/42 | 67/33 | 50/50 | 60/40 |
| Time since last corrective surgery, mean±SD (years) | 16±12 | 19±14 | 13±11 | 17±13 |
| In receipt of additional PAH treatment at baseline, n (%) | ||||
| No | 8 (67) | 8 (53) | 4 (50) | 20 (57) |
| Yes | 4 (33) | 7 (47) | 4 (50) | 15 (43) |
| ERA | 3 (25) | 5 (33) | 4 (50) | 12 (34) |
| Prostanoid | 1 (8) | 2 (13) | 0 | 3 (9) |
| 6MWD, mean±SD (m) | 360±59 | 369±78 | 391±59 | 371±11 |
6MWD, 6-min walking distance; CHD, congenital heart disease; ERA, endothelin receptor antagonist; PAH, pulmonary arterial hypertension; WHO FC, WHO functional class.